Authors of a related editorial note that survival data are still immature, and survival endpoints are expected in 2018 after a longer follow-up. “The results of the present study are therefore important and helpful for the design of new treatment strategies including nab-paclitaxel, especially for tailored investigations in selected subtypes, such as triple negative disease. Meanwhile, results from ongoing studies with a similar design (eg, the ETNA trial), as well as survival data, are required before any modification of current clinical practice can be made.”
There were no statistically significant differences in serious adverse effects between the two groups.